Predicting tenofovir concentration on the basis of renal factors determined by routine tests

American Journal of Therapeutics

Volumn 14, Issue 6, 2007, Pages 514-518

  Makie, Toshio ^a   Nagai, Satoko ^a   Sasakawa, Atsushi ^a   Kawamura, Kiyomi ^a   Kuwahara, Takeshi ^a  

^a OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

Blood urea nitrogen (BUN); Glomerular filtration rate (GFR); Human immunodeficiency virus (HIV); Plasma concentration; Tenofovir disoproxil fumarate (TDF)

Indexed keywords

CREATININE; NITROGEN; TENOFOVIR; UREA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DOSE KIDNEY FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL;

ADENINE; ADULT; AGED; ANTI-HIV AGENTS; BLOOD UREA NITROGEN; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; MIDDLE AGED; PHOSPHONIC ACIDS;

EID: 37349018687     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3180ed7346     Document Type: Article

References (26)

1. Schooley RT, Ruane P, Cheng AK, et al. Study 902 Team. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002;16:1257-1263.
2. Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS. 2004;18:1074-1076.
3. Verhelst D, Monge M, Rossert J, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002;40:1331-1333.
4. Karras A, Lafaurie M, Molina JM, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36:1070-1073.
5. Schaaf B, Aries SP, Kramme E, et al. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis. 2003;37:e41-e43.
6. James CW, Steinhaus MC, Szabo S, et al. Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy. 2004;24:415-418.
7. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J AIDS. 2004;35:269-273.
8. Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS. 2005;19:93-95.
9. Kinai E, Hanabusa H. Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. AIDS. 2005;19:2031-2033.
10. Cihlar T, Ho ES, Lin DC, et al. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001;20:641-648.
11. Schuetz JD, Connelly MC, Sun D, et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med. 1995;5:1048-1051.
12. Robbins BL, Connelly MC, Marshall DR, et al. A human T lymphoid cell variant resistant to the acyclic nucleoside phosphonate, 9-(2- phosphonylmethoxyethyl) adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent. Mol Pharmacol. 1995;47:391-397.
13. Taburet A-M, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48:2091-2096.
14. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classi-fication, and stratification. Am J Kidney Dis. 2002;39:1-266.
15. The Japanese Society of Nephrology. Special program at Japan KidneyWeek (JKW): #19. Fight against chronic kidney disease (part 2). Aug. 8, 2005. Available at: http://www.jsn.or.jp/jsn_new/eng/index_e.html. Accessed December 15, 2006.
16. Gallant AR, Fuller WA. Fitting segmented polynomial regression models whose join points have to be estimated. J Am Stat Assoc. 1973;68:144-147.
17. Gathery SB. Partition regression. J Am Stat Assoc. 1974;69:945-947.
18. Ertel JE, Forkles EB. Some algorithms for linear spline and piecewise multiple linear regression. J Am Stat Assoc. 1976;71:640-648.
19. Nakamura T. BMDP program for piecewise linear regression. Comput Method Programs Biomed. 1986;23:53-55.
20. Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med. 2004;117:282-284.
21. Creput C, Gonzalez-Canali G, Hill G, et al. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS. 2003;17:935-937.
22. Gaspar G, Monereo A, Garcia-Reyne A, et al. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution. AIDS. 2004;18:351-352.
23. Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42:283-290.
24. Winston A, Amin J, Mallon P, et al. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med. 2006;7:105-111.
25. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-1 infected adults. Antimicrob Agents Chemother. 2001;45:2733-2739.
26. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43:595-612.